Schizophrenia News

Increased gestational exposure to fortification of grain products with folic acid may protect against psychotic symptoms in offspring, according to findings published in JAMA Psychiatry.

Research published in European Psychiatry found that global cognitive functioning and severe depressive symptoms were the most robust predictors of suicidal behavior in patients after their first episode of non-affective psychosis.

Study findings published in Science indicate many common psychiatric disorders are connected on a genetic level.

The FDA has approved Aristada Initio for the initiation of Aristada, a long-acting injectable atypical antipsychotic medication, to treat adults with schizophrenia, according to a press release.

Over a 5-year period, more than one in 10 suicides in Ontario, Canada, were attributable to individuals with schizophrenia spectrum disorder, research findings revealed.

Children aged 7 years at familial high risk for schizophrenia spectrum disorders had widespread neurocognitive deficits; however, these impairments were not observed in children at familial high risk for bipolar disorder, research findings revealed.

Treatment with antirheumatic medications — such as NSAIDs and anticytokine monoclonal antibodies — may benefit patients with schizophrenia, according to data published in Psychiatric Annals.

Researchers found low-dose amisulpride was an effective and well-tolerated treatment for older patients with very late-onset schizophrenia-like psychosis.

Findings published in JAMA Psychiatry revealed a link between cannabis use frequency and increased psychosis symptoms at the individual level among Canadian adolescents.

Results from a systematic review and meta-analysis suggest that patients with current psychotic depression were at much higher risk for future psychotic depressive episodes than those with currently nonpsychotic MDD.